Ovarian Neoplasms
Conditions
Brief summary
Detection of the potential oncogenic role of Engrailed-2 in epithelial ovarian neoplasms, in order to detect biological markers that could be targeted and blocked by new medications.
Detailed description
Epithelial ovarian carcinomas represent more than 90% of all ovarian carcinomas. Treatment of these ovarian carcinomas on basis of their histopathological features didn't improve patients' outcomes with very high incidence of relapses and resistance to therapy. Detection of novel biological markers which are involved in tumor progression could have promising results if these biological molecules are targeted and blocked by new medications. Engrailed-2 is a protein encoded by a gene located on chromosome 7. Engrailed-2 is involved in neural development and neural connections during embryological life. it has been proved that Engrailed-2 is expressed in non neural neoplasms, especially in prostatic and urinary bladder carcinomas. Now estimatiion of urinary and serum levels of Engrailed-2 is used as a non-invasive screening tool in to detect prostatic and urinary bladder carcinomas. We aim to evaluated immunohistochemical expression of Engrailed-2 in normal and neoplastic ovarian tissues and to compare such expression between normal and neoplastic tissues in order to improve its oncogenic role in ovarian carcinoma.
Interventions
GENETICImmunohistochemical staining of normal and neoplastic ovarian tissues by anti human Engrailed-2 antibody.
Immunohistochemical staining of normal and neoplastic ovarian tissues by anti human Engrailed-2 antibody and compare levels of expression in different ovarian specimens to detect its potential role in oncogenesis of ovarian carcinoma.
Sponsors
Sohag University
Study design
Observational model
CASE_ONLY
Time perspective
RETROSPECTIVE
Eligibility
Sex/Gender
FEMALE
Age
20 Years to 70 Years
Inclusion criteria
* All types of epithelial ovarian neoplasms (benign, borderline and malignant).
Exclusion criteria
* Non-epithelial and/ or secondary ovarian tumors. * Cases with poor clinical data. * Cases who had history of pre-operative chemotherapy.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| compare levels of Engrailed-2 expression in different ovarian specimens. | December, 2021 | compare levels of immunohistochemical expression of Engrailed-2 in normal and neoplastic ovarian tissues. and correlate Engrailed-2 expression in neoplastic ovarian tissues to patients' ages, tumor phenotype and state of nodal metastasis. |
Countries
Egypt
Outcome results
None listed